Editas reports EDIT-301 (reni-cel) data: all 11 SCD patients free of vaso-occlusive events

Editas Medicine, Inc.

All 11 SCD patients in RUBY trial free of vaso-occlusive events post reni-cel; 6 with >=5 months follow-up achieved normal Hb and >40% fetal Hb.
6 TDT patients in EdiTHAL trial showed early robust total hemoglobin rise above 9 g/dL transfusion independence threshold.
Reni-cel well-tolerated in all 17 patients; safety profile consistent with myeloablative conditioning; no SAEs related to reni-cel reported.
Data presented at ASH and company webinar; additional dosing and further updates expected mid-2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.